Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Insulet Corporation
Taysha gains control of GAN candidate and program; BI licenses COMT inhibitors from Lieber Institute; plus three new gene therapy-driven tie-ups between biopharma and academia.
A trial of Insulet’s Omnipod 5 trial in children and adults showed improvements in time and range and hemoglobin A1c after three months of use compared to standard therapy.
Glooko will use the proceeds to expand into new geographies and take advantage of rising reimbursement for digital health, expand solutions for co-morbid conditions, and explore tuck-in acquisitions.
The global insulin pump market is expected to see double-digit growth, reaching $5.1bn in 2024, with product launches expected by Medtronic, Insulet, Tandem and smaller players in 2021.
- Medical Devices
- Other Names / Subsidiaries
- Insulet Canada Corporation
- Neighborhood Diabetes
- Neighborhood Holdings, Inc.